Orforglipron vs Tirzepatide
Comparing Eli Lilly's oral non-peptide GLP-1 agonist orforglipron with injectable dual GIP/GLP-1 agonist tirzepatide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Orforglipron
Dossier overview
Tirzepatide
Dossier overview
Overview
Orforglipron and tirzepatide represent different approaches to incretin therapy. Orforglipron is an oral, non-peptide, small molecule GLP-1 agonist taken daily, while tirzepatide is an injectable dual GIP/GLP-1 agonist given weekly. Both are from Eli Lilly, representing complementary portfolio options.
Mechanism Comparison
| Aspect | Orforglipron | Tirzepatide |
|---|---|---|
| Targets | GLP-1 only | GIP + GLP-1 |
| Molecule Type | Small molecule | Peptide |
| Route | Oral | Injectable |
Key Distinctions
Orforglipron advantages:
- Oral administration (no injections)
- Small molecule (easier manufacturing, storage)
- No food timing restrictions (unlike semaglutide oral)
- Potential cost advantages
Tirzepatide advantages:
- Dual agonism (GIP adds efficacy)
- Weekly dosing (less frequent)
- Higher weight loss demonstrated
- FDA approved
Evidence Comparison
| Aspect | Orforglipron | Tirzepatide |
|---|---|---|
| Development Phase | Phase 3 | FDA Approved |
| Key Trials | ACHIEVE program | SURMOUNT, SURPASS |
| Human Data | Phase 2 published | Extensive |
| Regulatory Status | Investigational | Approved (Mounjaro, Zepbound) |
Efficacy Comparison
Orforglipron (Phase 2)
| Dose | Weight Loss (36 weeks) |
|---|---|
| 36mg | ~9.4% |
| 45mg | ~10.1% |
Tirzepatide (SURMOUNT-1)
| Dose | Weight Loss (72 weeks) |
|---|---|
| 5mg | ~15% |
| 10mg | ~19.5% |
| 15mg | ~22.5% |
Key point: Tirzepatide shows greater weight loss, likely due to dual agonism.
Regulatory Status
| Aspect | Orforglipron | Tirzepatide |
|---|---|---|
| FDA Status | Phase 3 | Approved |
| Indications | Obesity, T2D (in trials) | T2D, Obesity |
| Brand Names | N/A | Mounjaro, Zepbound |
| Expected Approval | 2025-2026 | Already approved |
Administration Comparison
| Factor | Orforglipron | Tirzepatide |
|---|---|---|
| Route | Oral tablet | Subcutaneous injection |
| Food Restrictions | None | None (injectable) |
| Storage | Room temperature | Refrigerated |
| Self-administration | Simple | Requires injection technique |
Patient Preference Considerations
| Factor | Oral (Orforglipron) | Injectable (Tirzepatide) |
|---|---|---|
| Needle phobia | No barrier | Barrier for some |
| Daily compliance | Required | Less frequent |
| Travel convenience | Easier | Requires cold chain |
| Perceived efficacy | Lower (GLP-1 only) | Higher (dual agonist) |
Side Effect Profile
| Effect | Orforglipron | Tirzepatide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Discontinuation | ~10-15% (Phase 2) | ~5-7% |
GI effects are class-related; oral route doesn’t eliminate them.
Manufacturing and Access
| Factor | Orforglipron | Tirzepatide |
|---|---|---|
| Molecule Type | Small molecule | Peptide |
| Manufacturing | Chemical synthesis | Biologic production |
| Scalability | Potentially easier | More complex |
| Supply Challenges | TBD | Current shortages |
| Generic Potential | Standard small molecule | Biologic complexity |
Small molecule manufacturing may help address supply constraints.
Cost Considerations
| Factor | Orforglipron | Tirzepatide |
|---|---|---|
| Expected Pricing | TBD | ~$1,000+/month (US) |
| Manufacturing Cost | Potentially lower | Higher (peptide) |
| Insurance Coverage | TBD | Variable |
Key Differences
- Efficacy: Tirzepatide shows greater weight loss (dual agonism)
- Convenience: Orforglipron is oral (no injections)
- Frequency: Orforglipron daily vs tirzepatide weekly
- Approval status: Tirzepatide approved; orforglipron investigational
- Molecule type: Small molecule vs peptide
Portfolio Strategy
Eli Lilly’s approach:
- Tirzepatide: Maximum efficacy, injectable
- Orforglipron: Oral option, broader access
- Retatrutide: Next-gen triple agonist (pipeline)
Different patient populations may prefer different options.
Summary
- Orforglipron offers oral convenience with ~10% weight loss - suitable for patients preferring pills
- Tirzepatide provides superior efficacy (~20%+ weight loss) but requires weekly injections
- Dual agonism appears to confer efficacy advantage over GLP-1 alone
- Market may segment by patient preference and indication severity
- Both likely to have roles in obesity treatment
This comparison is for educational purposes only. Orforglipron is investigational. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.